Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Non-Interventional, Retrospective Study Aims to Estimate the Prevalence and Describe the Clinical Manifestations of HER2-Low Breast Cancer Reported in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2- Negative From Patient Medical Records in The Gulf Council Cooperation Region

NCT06125314 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06125314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06125314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Non-Interventional, Retrospective Study Aims to Estimate the Prevalence and Describe the Clinical Manifestations of HER2-Low Breast Cancer Reported in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2- Negative From Patient Medical Records in The Gulf Council Cooperation Region
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 5, 2024
Completion date
September 30, 2024
Enrollment
517 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast carcinoma, breast neoplasms, genes, her2